July 31, 2024

HEMGENIX Has Been Administered Across The U.S.

Administered in Green Bay

HEMGENIX is revolutionizing treatment with its groundbreaking one-time infusion that offers elevated and sustained factor IX levels for years. Approved by the FDA in 2022, HEMGENIX has been the focus of extensive research for many years, promising new hope for patients.

We are thrilled to highlight a significant achievement within our team. Andrea Buxton, APNP, one of HOC’s Nurse Practitioners, recently shared her invaluable insights on the preparation and administration experiences for the first two patients to be commercially dosed with HEMGENIX. Her contributions are not only a testament to her expertise but also underscore the innovative spirit that drives our organization.

For more information check out the FAQ’s from HEMGENIX website:

.

 

Recent Posts

Welcome to Beyond the Bleeds

Welcome to Beyond the Bleeds! In this very first episode, John and I are excited to introduce ourselves and lay the foundation for a community centered around life with bleeding disorders. Whether you're managing hemophilia, von Willebrand disease, or any rare...

Latest Advances in Bleeding Disorder Research

Innovative Treatments on the Horizon Bleeding disorders, which impair the body’s ability to clot blood, have long posed significant challenges for both patients and healthcare providers. Advances in bleeding disorder research are crucial for developing innovative...

2025 Open Enrollment

Open Enrollment Season is approaching again! There are a few questions you need to ask when choosing an insurance plan if you or a family member have a bleeding disorder diagnosis. How do you get your insurance? Do you get your insurance from an employer...

Social Media